Equities Analysts Set Expectations for GPCR Q1 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Structure Therapeutics in a research note issued on Monday, March 3rd. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings of ($0.24) per share for the quarter. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics' Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.29) EPS, FY2025 earnings at $1.80 EPS and FY2029 earnings at $1.03 EPS.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01.

A number of other brokerages have also recently commented on GPCR. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus began coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price target on the stock. William Blair assumed coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an "outperform" rating for the company. Finally, JMP Securities reiterated a "market outperform" rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $81.29.

Remove Ads

Structure Therapeutics Stock Performance

Shares of NASDAQ:GPCR traded down $0.91 during midday trading on Tuesday, hitting $22.62. 636,425 shares of the company's stock traded hands, compared to its average volume of 823,078. Structure Therapeutics has a twelve month low of $19.61 and a twelve month high of $62.74. The company has a market cap of $1.30 billion, a PE ratio of -30.57 and a beta of -2.37. The firm's fifty day moving average price is $26.10 and its two-hundred day moving average price is $33.22.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after purchasing an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $34,000. Assetmark Inc. lifted its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock worth $58,000 after purchasing an additional 719 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in Structure Therapeutics in the fourth quarter worth about $40,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.